Carl Zeiss Meditec AG : Heavy volume on Carl Zeiss
Entry price | Target | Stop-loss | Potential |
---|
€22.4 |
€24.5 |
€21.6 |
+9.38% |
---|
There are heavy volumes on Carl Zeiss which is trading in a tight price range and is approaching a strong resistance level.
From a fundamental viewpoint, the group offers an interesting value compared to its peers, as it is valued 1.58 times its sales according to Thomson Reuters analysts. Moreover, revenues and benefits are improving and this trend should continue until 2018 and its financial situation should continue to improve with a positive cash position every year.
Since its fall, the stock fluctuates in a trading range between EUR 19.8 and EUR 22.4. The stock has renewed its bullish trend and is now reaching a strong resistance level. The support of the 20-day moving average confirmed that the breakout of this level will be a bullish signal.
Therefore, thanks to its graphical pattern and its strong fundamentals, active investors could take a long position in Carl Zeiss above EUR 22.4. The target price will be EUR 24.5. A stop loss order can be placed under EUR 21.8 in case of failure of the bullish overflow.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.